News

BlogsPosts
As Seen In
Canadian Technology and Innovation: making strides in the global cell therapy landscape
Another cell therapy rising star, RepliCel Life Sciences, is harnessing the
BlogsPosts
As Seen In
RepliCel's regenerative technology could take the "Polar Silk Road" to China
New opportunities are arising at every turn for the regenerative medicine
BlogsPosts
As Seen In
RepliCel CEO: Anticipating the Approval of Their Dermal Injector, its Impact in Europe and Beyond
Click here to read the full article and interview as it appears
BlogsPosts
Press Release
RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector
Delivery of RepliCel’s patented prototypes kick-starts functional testing, matures licensing discussions, and confirms commercialization schedule VANCOUVER,
BlogsPosts
As Seen In
Analyst Says Cell Therapy Company’s Move Decreases Risk
Click here to read the full article as
BlogsPosts
As Seen In
RepliCel Poised To Partner Up For Precision-Control Dermal Injector
To preview the interview with Tina Tan as it appears on Medtech.com, click here. (6/23/17)
BlogsPosts
As Seen In
Exclusive Interview with RepliCel Life Sciences President and CEO Lee Buckler
To read the full article as it appears on SmarterAnalyst.com by Julie Lamb, click here.
BlogsPosts
Press Release
RepliCel CEO Provides Company Outlook
A data-rich 2017 positions RepliCel for maturity through the next phase of its product development,
BlogsPosts
Press Release
United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies
With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to
BlogsPosts
As Seen In
RepliCel Developing Autologous Cell Therapies For Skin, Hair and Tendon Regeneration
To read the full interview as it appears on MedicalResearch.com, click here. (4/22/17)
BlogsPosts
Press Release
RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector
VANCOUVER, BC – February 28, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”
BlogsPosts
Press Release
RepliCel Announces European Patents for its Innovative Dermal Injector Technologies
RCI-02, RepliCel’s nearest-term commercial asset, enables game-changing reliability, reproducibility, and programmability of three-dimensional skin
BlogsPosts
As Seen In
RepliCel – Using Cells for Healing
View featured company Article on Advisor Access click here
BlogsPosts
As Seen In
RepliCel CEO Lee Buckler talks to Cantech Letter
View Article by Nick Waddell on Cantech Letter click here
BlogsPosts
Press Release
RepliCel Announces CEO Update
Milestones for 2016 include two clinical trial readouts, finalizing RCI-02 for a 2017 product launch,
BlogsPosts
Press Release
RepliCel Receives European Patent for its Innovative Dermal Injector Technology
RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic
BlogsPosts
As Seen In
Canada’s emerging cell therapy biotech industry
Canadian companies driving global breakthroughs in regenerative medicine By Kathryn Boothby To read this article
BlogsPosts
Press Release
RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype
Novel features of next-generation design promise to serve and expand the dermal injectable market VANCOUVER, BC
BlogsPosts
As Seen In
5 Questions with David Hall
Click here to view the article on Cantech Letter Vancouver-based RepliCel Life Sciences (TSXV:RP)
BlogsPosts
As Seen In
Stockhouse: RepliCel Hits Lucrative Bio-med Trifecta with Innovative Tech
To read the article on Stockhouse click here Until 2011, RepliCel Life

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.